- Hikma Pharmaceuticals has confirmed that its venture capital arm, Hikma Ventures invested in , the next generation minimally-invasive biosensor technology company, in collaboration with M Ventures which led the $10m series A round of financing.

Lana Ghanem, Managing Director of Hikma Ventures and Edward Kliphuis, Investment Director of the New Businesses fund at M Ventures will be joining the Biolinq Board of Directors.

Lana Ghanem, Managing Director of Hikma Ventures, said, "Diabetes is a chronic disease affecting millions of people worldwide with a high prevalence in the Middle East and North Africa. We enjoyed working alongside the M Ventures team on closing this investment and we look forward to working with the Biolinq team and our other co-investors to bring this technology to patients."

"We are leading this round of investment with an excellent group of co-investors, all with the same goal of making the convenient and painless monitoring of multiple biomarkers a reality for patients in need," said Edward Kliphuis, investment director of the New Businesses fund at M Ventures. "As investors, we fully recognize the value of Biolinq's skin-applied, minimally-invasive electrochemical biosensor platform technology."

Jared Tangney, CEO of Biolinq, said, "This funding round will fuel the growth of our technology platform. Our first product is not just another CGM technology, but a platform we built from the ground up with a focus on the end user. Our vision is to utilize our novel manufacturing approach to achieve low-cost and high uniformity, enabling factory calibration (no finger sticks) in a nickel-sized patch. With our low cost-of-goods and ease-of-use, we plan to increase access to CGM and simplify diabetes management."

At 1:49pm: [LON:HIK] Hikma Pharmaceuticals PLC share price was -2p at 1050p

Story provided by